RxDoctor Payments Data

Humaira Khalid, MD

Internal Medicine · Greer, SCNPI 1689642217

Payments from drug & device makers

$5,234in general payments, 2019–2025

Across 309 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$808
  • AstraZeneca$530
  • AbbVie$404
  • Abbott$318
  • Novartis$317
  • Lilly USA, LLC$317
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$5,234100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,234 in reported general payments places this provider in the 85th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$172,156
Medicare patients
379
Services billed
2,920

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide158$195,044
OzempicSemaglutide135$146,949
EliquisApixaban72$81,419
JardianceEmpagliflozin42$56,131
FarxigaDapagliflozin Propanediol58$47,383
MyrbetriqMirabegron55$42,836
JanuviaSitagliptin Phosphate55$38,159
RybelsusSemaglutide23$37,790
TrulicityDulaglutide21$24,500
LinzessLinaclotide12$15,952
Breo ElliptaFluticasone/Vilanterol38$14,906
Combivent RespimatIpratropium/Albuterol Sulfate17$8,156
Effexor XrVenlafaxine Hcl11$7,645
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$7,352
Atorvastatin Calcium566$5,242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$317$219,544179 claims
Novo NordiskOzempic, Rybelsus$808$184,739158 claims
PfizerEliquis, Effexor Xr$128$89,06483 claims
Boehringer IngelheimJardiance, Combivent Respimat$145$64,28759 claims
AstraZenecaFarxiga$530$47,38358 claims
Astellas Pharma US IncMyrbetriq$173$42,83655 claims
MerckJanuvia$110$38,15955 claims
AbbVieLinzess, Synthroid$404$17,69849 claims
GSKBreo Ellipta$193$14,90638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Greer

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →